http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#Head http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#provenance http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#pubinfo http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion http://purl.obolibrary.org/obo/DOID_3310 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3310 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00591 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association http://www.w3.org/2000/01/rdf-schema#label fluocinolone acetonide topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients 1 1 topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks 1 2 limitations of use apply the least amount to cover affected areas discontinue when disease is controlled 1 3 do not use in the diaper area 1 3 do not use on the face axillae or groin 1 3 6 2 8 4 fluocinolone acetonide topical oil is indicated for the topical treatment of atopic dermatitis in adult patients fluocinolone acetonide topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks safety and effectiveness in pediatric patients younger than 3 months of age have not been established apply the least amount of fluocinolone acetonide topical oil needed to cover the affected areas as with other corticosteroids fluocinolone acetonide topical oil should be discontinued when control of disease is achieved contact the physician if no improvement is seen within 2 weeks fluocinolone acetonide topical oil should not be applied to the diaper area diapers or plastic pants may constitute occlusive use fluocinolone acetonide topical oil should not be used on the face axillae or groin unless directed by the physician application to intertriginous areas should be avoided due to the increased risk of local adverse reactions see adverse reactions 6 use in specific populations 8 4 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00591 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#provenance http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#pubinfo http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig http://purl.org/nanopub/x/hasSignature dhPjKHDgRl04VP4r8coGQM2wjZ5Xvu7O7oDJhOLFttjd0x8QiqwT1ZoeYRQF9PAbEm3/egcj8TDLZ08Yg5dW8Bxbd80DC7j7/f1PKCBQxX6EMja/ZLdMeNtUB1LjOyKAXzQl3Uu1beCeid1iPthRKv3kVX44pEbKjdxGEi505kY= http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://purl.org/dc/terms/created 2021-06-27T20:42:27.644+02:00 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs